Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)

SHE:002727 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	2,432	3,418	3,676	3,512	2,235	1,624
Short-Term Investments	-	-	219.66	-	-	1,433
Trading Asset Securities	765.04	-	-	8.36	297.3	-
Cash & Short-Term Investments	3,197	3,418	3,895	3,520	2,532	3,057
Cash Growth	-1.20%	-12.26%	10.66%	39.00%	-17.16%	27.91%
Accounts Receivable	1,743	1,613	1,555	1,776	1,376	846.91
Other Receivables	317.5	319.49	313.3	307.29	206.63	150.18
Receivables	2,060	1,932	1,868	2,083	1,583	997.09
Inventory	3,620	4,088	3,853	3,387	3,317	2,194
Prepaid Expenses	-	3.49	1.03	0.14	0.16	0.01
Other Current Assets	268.4	270.29	275.63	467.06	260.12	469.49
Total Current Assets	9,146	9,712	9,893	9,458	7,692	6,718
Property, Plant & Equipment	3,555	3,956	3,951	3,994	4,080	690.52
Long-Term Investments	147.92	136.52	143.26	352.46	107.22	83.64
Goodwill	1,983	1,983	1,650	1,397	1,380	1,102
Other Intangible Assets	221.29	196.86	178.08	165.67	122.89	122.88
Long-Term Deferred Tax Assets	110.48	93.7	88.94	94.11	58.46	27.62
Long-Term Deferred Charges	648.85	724.03	661.17	629.9	590.75	530.72
Other Long-Term Assets	28.16	29	82.31	88.59	305.71	52.71
Total Assets	15,841	16,830	16,647	16,179	14,337	9,328
Accounts Payable	4,492	4,916	4,339	4,329	3,806	2,876
Accrued Expenses	232.83	539.54	681.48	518.75	295.38	328.78
Short-Term Debt	537.77	495.57	468.6	402.57	127.7	60.06
Current Portion of Long-Term Debt	907.99	-	1.8	0.2	4.02	-
Current Portion of Leases	-	1,005	975.88	932.77	1,012	-
Current Income Taxes Payable	136.47	53.62	81.37	197.86	118.4	54.53
Current Unearned Revenue	106.82	116.9	113.72	156.61	105.18	67.15
Other Current Liabilities	564.72	504.61	537.55	339.23	415.09	145.71
Total Current Liabilities	6,979	7,631	7,200	6,877	5,884	3,532
Long-Term Debt	114.81	-	-	1.8	35.08	-
Long-Term Leases	1,257	1,531	1,552	1,757	1,729	-
Long-Term Unearned Revenue	17.28	11.55	14.54	12.15	13.34	15.79
Long-Term Deferred Tax Liabilities	3.47	3.55	3.93	4.05	3.56	-
Total Liabilities	8,371	9,177	8,770	8,652	7,665	3,548
Common Stock	585.6	585.6	596.01	596.02	596.18	595.31
Additional Paid-In Capital	2,013	2,019	2,144	2,147	2,157	2,097
Retained Earnings	4,868	4,886	5,011	4,700	3,869	3,126
Treasury Stock	-150	-	-4.24	-22.69	-46.86	-53.37
Comprehensive Income & Other	-	-	-	6.19	2.93	0.32
Total Common Equity	7,317	7,491	7,746	7,426	6,578	5,765
Minority Interest	152.5	162.27	131.04	101.44	94.8	15.09
Shareholders' Equity	7,470	7,653	7,877	7,528	6,673	5,780
Total Liabilities & Equity	15,841	16,830	16,647	16,179	14,337	9,328
Total Debt	2,817	3,031	2,998	3,094	2,908	60.06
Net Cash (Debt)	379.95	386.58	896.84	425.94	-375.58	2,997
Net Cash Growth	212.36%	-56.90%	110.56%	-	-	57.15%
Net Cash Per Share	0.65	0.65	1.50	0.72	-0.63	5.23
Filing Date Shares Outstanding	574.13	585.6	596.01	596.02	596.18	595.31
Total Common Shares Outstanding	574.13	585.6	596.01	596.02	596.18	595.31
Working Capital	2,167	2,080	2,693	2,581	1,809	3,186
Book Value Per Share	12.74	12.79	13.00	12.46	11.03	9.68
Tangible Book Value	5,113	5,311	5,918	5,863	5,075	4,540
Tangible Book Value Per Share	8.91	9.07	9.93	9.84	8.51	7.63
Buildings	-	892.7	894.92	785.07	741.03	576.73
Machinery	-	447.47	416.9	385.35	350.85	293.68
Construction In Progress	-	35.79	9.81	3.87	25.47	15.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.